


Amendments to the Claims:

This listing of the claims will replace all prior versions and listings of claims in the application:




B2

1. (Currently Amended) A compound according to formula (I):



wherein:


R¹ is ~~Het~~ or Ar




or

in which R¹ is C₁₋₄alkyl and R'' is phenyl, benzyl or -CH₂CF₃; or R¹ and R'' are joined to form a morpholinyl ring;

R² is



or




;


or a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. (Original) A compound according to claim 1 in which R^2 is:



4. (Original) A compound according to claim 1 in which R^2 is:



5. (Original) A compound which is:

(\pm)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-(trifluoromethyl)phenyl]butanoic acid;

(\pm)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-[(N-methyl-N-phenylamino)carbonyl]-1,3-oxazol-2-yl]butanoic acid;

(\pm)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-[(morpholin-4-yl)carbonyl]-1,3-oxazol-2-yl]butanoic acid;

(\pm)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-[[N-methyl-N-(2,2,2-trifluoroethyl)amino]carbonyl]-1,3-oxazol-2-yl]butanoic acid;

(\pm)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-[4-(trifluoromethyl)thiazol-2-yl]butanoic acid;

(\pm)-4-[4-[2-[6-(methylamino)pyridin-2-yl]-1-ethoxy]phenyl]-3-(3-methylthiazol-2-yl)butanoic acid;

(S)-3-(3-fluorophenyl)-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]butanoic acid;

(\pm)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(pyridin-3-yl)butanoic acid;

(S)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(pyridin-3-yl)butanoic acid;
or
(S)-3-(pyridin-3-yl)-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]butanoic acid;
or a pharmaceutically acceptable salt thereof.

6. (Previously presented) A pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier.

B1
cont 7. (Withdrawn) A pharmaceutical composition which comprises a compound according to claim 1, an antineoplastic agent and a pharmaceutically acceptable carrier.

8. (Withdrawn) The pharmaceutical composition according to claim 6 wherein the antineoplastic agent is topotecan or cisplatin.

9. (Withdrawn) A pharmaceutical composition which comprises a compound according to claim 1, an inhibitor of bone resorption and a pharmaceutically acceptable carrier.

10. (Withdrawn) A method of treating a disease state in which antagonism of the $\alpha_v\beta_3$ receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.

11. (Withdrawn) A method of treating a disease state in which antagonism of the $\alpha_v\beta_5$ receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.

12. (Original) A method of treating osteoporosis which comprises administering to a subject in need thereof a compound according to claim 1.

13. (Withdrawn) A method for inhibiting angiogenesis, tumor growth or tumor metastasis which comprises administering to a subject in need thereof a compound according to claim 1.

14. (Withdrawn) A method of treating atherosclerosis, restenosis or rheumatoid arthritis which comprises administering to a subject in need thereof a compound according to claim 1.

15. (Withdrawn) A method of inhibiting tumor growth which comprises administering stepwise or in physical combination a compound according to claim 1 and an antineoplastic agent.

132
cor 16. (Withdrawn) The method according to claim 15 wherein the antineoplastic agent is topotecan or cisplatin.

17. (Withdrawn) A method of treating osteoporosis or inhibiting bone loss which comprises administering stepwise or in physical combination a compound according to claim 1 and an inhibitor of bone resorption.

Claims 18-26 (Cancelled)